



Read our COVID-19 research and news.

Advertisement

EDITORS' CHOICE | VACCINES

Livening up pertussis vaccine development

Michelle Boyle

+ See all authors and affiliations

Science Translational Medicine 05 Feb 2020:
Vol. 12, Issue 529, eaba9014
DOI: 10.1126/scitranslmed.aba9014

Article

Info & Metrics

eLetters

Become a Member

Log In ScienceMag.org



Get the latest issue of *Science Translational Medicine* delivered right to you!

Despite consistent vaccine efforts globally, pertussis infection remains a substantial global health burden with devastating consequences for infants. Acellular pertussis vaccines (aPV) do not protect from nasal colonization nor induced long lasting and highly efficacious protection. Indeed, the replacement of the whole-cell pertussis vaccine with aPV in the 1990s is a likely contributor to ongoing transmission and lack of control of this disease. BPZE1, a live attenuated vaccine candidate, has shown considerable promise in both mice and baboons. Importantly, this vaccine candidate both induces immune responses that protect from disease and also prevent nasal colonization. Thus, it has the potential to reduce global incidence.

Lin *et al.* follow the induction of antibodies and cellular immunity in responses to BPZE1 in a small human clinical trial. They show that a single intranasal dose of BPZE1 in young adults induces a robust immunoglobulin G (IgG) and IgA response, accompanied by a T helper 1 (T_H1)-biased CD4 T cell activation, including within the circulating T follicular helper cell subset. Although induced IgG antibodies were at a lower magnitude than seen in aPV vaccine recipients in a separate study, BPZE1-induced antibodies were more strongly skewed to cytophilic subclasses and had superior functionality, with a higher capacity to induce reactive oxygen species release from neutrophils. These two features are likely important in mediating protection. Further, the antibody response following BPZE1 recognized a broader array of antigens compared with aPV vaccination responses. Overall, data shows that BPZE1 has great promise as an improved pertussis vaccine and is, as such, currently undergoing further clinical trials.

This study highlights the potential of live attenuated vaccine approaches to tackle important global infections. Further, data show the value of comprehensive studies of vaccine induced immunity in humans to understand induced immunity and to develop new strategies to further optimize vaccinations. Future studies are required to investigate how prior exposure to aPV or pertussis infection may impact BPZE1 vaccine responses and immunogenicity, and, most importantly, to assess whether BPZE1 vaccination in humans can prevent disease and nasal colonization.

Highlighted Article

A. Lin, D. Apostolovic, M. Jahnmatz, F. Liang, S. Ols, T. Tecleab, C. Wu, M. van Hage, K. Solovay, K. Rubin, C. Loch, R. Thorstensson, M. Thalen, K. Loré. Live attenuated pertussis vaccine BPZE1 induces a broad antibody response

[Become a Member](#)

[Log In](#) [ScienceMag.org](#)



Recommended articles from TrendMD

VP4- and VP7-specific antibodies mediate heterotypic immunity to rotavirus in humans

Ningguo Feng et al., *Sci Transl Med*, 2017

Immune history profoundly affects broadly protective B cell responses to influenza.

Sarah F Andrews et al., *Sci Transl Med*, 2015

Broadening vaccine strategies to induce HIV broadly neutralizing antibodies

Michelle Boyle, *Sci Transl Med*, 2019

Strong TH1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy

Venkateswarlu Chamcha et al., *Sci Transl Med*, 2019

The right adjuvant gives T follicular helper cells a boost

Michelle Boyle, *Sci Transl Med*, 2019

Outer Membrane Vesicles (OMV)-based and Proteomics-driven Antigen Selection Identifies Novel Factors Contributing to *Bordetella pertussis* Adhesion to Epithelial Cells

Gianmarco Gasperini et al., *MCP*, 2018

Identification of global regulators of T-helper cell lineage specification

Kartiek Kanduri et al., *Genome Med*, 2015

Schistosoma mansoni antigen Sm-p80: prophylactic efficacy using TLR4 agonist vaccine adjuvant glucopyranosyl lipid A-Alum in murine and non-human primate models

Weidong Zhang et al., *Journal of Investigative Medicine*, 2018


Structural and Nonstructural Viral Proteins Are Targets of T-Helper Immune Response against Human Respiratory Syncytial Virus*

Elena Lorente et al., *MCP*, 2016

The use of systems biology and immunological big data to guide vaccine development

Christoph J. Blohmke et al., *Genome Med*, 2015

Powered by **TREND MD**



Science Translational Medicine

Vol 12, Issue 529
05 February 2020

[Table of Contents](#)

ARTICLE TOOLS

[Email](#)

[Alerts](#)

[Request Permissions](#)

[Citation tools](#)

[Become a Member](#)

[Log In](#) [ScienceMag.org](#)

STAY CONNECTED TO SCIENCE TRANSLATIONAL MEDICINE



- [Twitter](#)

Advertisement

SIMILAR ARTICLES IN:

- [Google Scholar](#)

[Become a Member](#)

[Log In](#) [ScienceMag.org](#)



Related Jobs

Ellison Endowed Chair Faculty Position

UC Davis Department of Orthopaedic Surgery
Sacramento, California

Postdoctoral Fellows Recruitment Announcement (2020) China -US (Henan) Hormel Cancer Institute

China-US (Henan) Hormel Cancer Institute
Zhengzhou, Henan (CN)

Director of Healthcare Delivery Sciences

Sanford Research
Sioux Falls, South Dakota

[MORE JOBS ►](#)

NAVIGATE THIS ARTICLE

- [Article](#)
 - [Abstract](#)
 - [Highlighted Article](#)
- [Info & Metrics](#)
- [eLetters](#)

[Become a Member](#)

[Log In](#) [ScienceMag.org](#)



Moving academic research forward during COVID-19

ECONOMICS

Discounting lives

SCI COMMUN

News at a glance

ECOLOGY

Costs and benefits of living with predators

Table of Contents

WORKING LIFE

Helping others—and myself

Get Our E-Alerts

Receive emails from *Science*. [See full list](#)

- Science Translational Medicine* TOC
- Science* Daily News
- Weekly News Roundup
- Science* Editor's Choice
- First Release Notification

United States ▼

Email address*

I also wish to receive emails from AAAS/*Science* and *Science* advertisers, including information on products, services, and special offers which may include but are not limited to news, career information, & upcoming events.

Sign up today

Required fields are indicated by an asterisk (*)

About Us

Journals

[Become a Member](#)

[Log In](#) [ScienceMag.org](#)

Advertising kits

Awards and Prizes
Custom Publishing
Webinars

For Authors

Submit
Information for Authors
Editorial Policies

For Librarians

Manage Your Institutional Subscription
Information for Librarians
Request a Quote
FAQs

Related Sites

AAAS.org
EurekaAlert!
Science in the Classroom
Science Magazine Japanese

Help

Access and Subscriptions
Order a Single Issue
Reprints and Permissions
Contact Us
Accessibility

Stay Connected



© 2020 American Association for the Advancement of Science. All rights reserved. AAAS is a partner of HINARI, AGORA, OARE, CHORUS, CLOCKSS, CrossRef and COUNTER.
Science Translational Medicine ISSN 1946-6242.

Terms of Service
Privacy Policy
Contact AAAS